<DOC>
	<DOCNO>NCT01562158</DOCNO>
	<brief_summary>This trial conduct Asia , Europe Oceania . The aim trial evaluate efficacy placebo activate recombinant human factor VII patient undergone allogeneic autologous stem cell transplantation .</brief_summary>
	<brief_title>Efficacy Safety Activated Recombinant Human Factor VII Treatment Bleeding Patients Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Patients undergone allogeneic autologous stem cell transplantation Known suspect allergy trial product Participation trial unapproved drug trial equal similar objective</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>